Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Research output: Contribution to journalArticle

Bibtex

@article{9d49128d481e4770b1904102eca35e30,
title = "Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.",
abstract = "Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.",
author = "Elizabeth Poplin and Harpreet Wasan and Lindsey Rolfe and Mitch Raponi and Tone Ikdahl and Ihor Bondarenko and Irina Davidenko and Volodymyr Bondar and August Garin and Stefan Boeck and Steffen Ormanns and Volker Heinemann and Claudio Bassi and Evans, {T R Jeffrey} and Roland Andersson and Hejin Hahn and Vince Picozzi and Adam Dicker and Elaina Mann and Cynthia Voong and Paramjit Kaur and Jeff Isaacson and Andrew Allen",
year = "2013",
doi = "10.1200/JCO.2013.51.0826",
language = "English",
volume = "31",
pages = "4453--4461",
journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
issn = "1527-7755",
publisher = "American Society of Clinical Oncology",
number = "35",

}